合肥晶合集成电路股份有限公司 第二届监事会第十五次会议决议公告 本公司监事会及全体监事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、监事会会议召开情况 证券代码：688249 证券简称：晶合集成 公告编号：2025-056 （二）审议并通过《关于公司<2025 年半年度募集资金存放与实际使用情况 的专项报告>的议案》 监事会认为：公司 2025 年半年度募集资金的存放与使用符合《上海证券交 易所科创板股票上市规则》《上市公司募集资金监管规则》等法律、法规、规范 性文件以及公司《募集资金管理制度》等规定，对募集资金进行了专户存储和专 项使用，并及时履行了相关信息披露义务，募集资金的存放与使用情况同公司募 集资金相关信息披露的内容一致，不存在变相改变募集资金用途和损害股东利益 的情况，不存在违规使用募集资金的情形。因此，监事会同意《晶合集成 2025 年半年度募集资金存放与实际使用情况的专项报告》的内容。 表决情况：3 票赞成；0 票弃权；0 票反对。 具体内容详见公司同日披露于上海证券交易所网站（www.sse.com.cn）的《晶 合集成 ...

本公司监事会及全体监事保证公告内容不存在任何虚假记载、误导性陈述或者重 大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 江苏康为世纪生物科技股份有限公司(下称"公司")第二届监事会第十四次会议于 席陈胜兰主持。 本次会议的召集、召开符合《中华人民共和国公司法》等法律法规以及《公司章程》 的相关规定，会议决议合法、有效。 证券代码：688426 证券简称：康为世纪 公告编号：2025-034 江苏康为世纪生物科技股份有限公司 一、审议通过《关于<2025 年半年度报告>及其摘要的议案》 监事会认为：公司《2025 年半年度报告》及其摘要的编制和审议程序符合相关法律 法规及《公司章程》等内部规章制度的规定，内容与格式符合《公开发行证券的公司信 息披露内容与格式准则第 3 号—半年度报告的内容与格式（2021 年修订）》、《公开发行 证券的公司信息披露编报规则第 15 号——财务报告的一般规定（2023 年修订）》等有关 文件的要求，真实、准确、完整地反映了公司 2025 年上半年的财务状况和经营成果等 事项，不存在任何虚假记载、误导性陈述或重大遗漏。 规定，对募集资金进行了专户存储和专项使用，及时履 ...

Meeting Overview - The shareholder meeting is scheduled for September 15, 2025, at 14:40 [1] - The meeting will be held at Jiangsu Kangwei Century Biotechnology Co., Ltd., located at 18 Zelan Road, Taizhou, Jiangsu Province [1] - Voting will be conducted through both on-site and online methods using the Shanghai Stock Exchange's network voting system [1] Voting Procedures - The online voting period is from September 15, 2025, during trading hours [1] - Specific voting times for the trading system are from 9:15-9:25, 9:30-11:30, and 13:00-15:00 [1] - Shareholders must complete identity verification to vote online for the first time [3] Agenda Items - The meeting will review several proposals, including: - The completion of certain fundraising investment projects and the permanent allocation of surplus funds to working capital [2] - The cancellation of the supervisory board and amendments to the company's articles of association [2] - The revision of the fund occupation prevention system for controlling shareholders and related parties [2] - The establishment of a remuneration management system for directors and senior management [2] Attendance and Registration - Shareholders registered by the close of trading on September 9, 2025, are eligible to attend [3] - Proxy representation is allowed, with specific documentation required for registration [4] - Registration must be completed by September 12, 2025, at 17:00 [5] Contact Information - The company’s contact address is Jiangsu Kangwei Century Biotechnology Co., Ltd., 4th Floor, Securities Affairs Department, 18 Zelan Road, Taizhou, Jiangsu Province [5] - Contact number: 0523-86200880, Contact person: Wang Tao [5]

Fundraising Overview - The company raised a total of RMB 75,015.00 million through the issuance of 33.34 million shares at RMB 22.50 per share, with actual funds received amounting to RMB 69,139.73 million after deducting issuance costs of RMB 9,097.20 million [1][2] - As of June 30, 2025, the company has used RMB 66,119.20 million of the raised funds, with RMB 54,485.68 million allocated to project expenditures [2][3] Fund Management - The company has established a fundraising management system to ensure the proper storage, approval, usage, and supervision of the raised funds, adhering to principles of regulation, safety, efficiency, and transparency [2][3] - The company has signed tripartite supervision agreements with banks to manage the special accounts for the raised funds, ensuring compliance with regulatory requirements [2][3] Fund Usage - As of June 30, 2025, the company has invested RMB 54,485.68 million in related projects, with no early investments or replacements reported during the reporting period [3][4] - The company has not used idle funds to temporarily supplement working capital or for any other purposes during the reporting period [3][4] Cash Management - The company has approved the use of up to RMB 15,000 million of temporarily idle funds for cash management, investing in safe and liquid financial products [3][4] - As of June 30, 2025, the company has allocated RMB 11,000 million in cash management products, including structured deposits with various banks [3][4] Project Status - The company has adjusted the expected completion date for the "Medical Endoscope Production Base Construction Project" to August 2026, with internal investment structure adjustments approved [3][4] - No changes to the fundraising investment projects have been reported during the reporting period [3][4]

Group 1 - The seventh supervisory board meeting of Sichuan Shengda Forestry Industry Co., Ltd. was held, with all three participating supervisors voting in favor of the resolutions [1][2] - The supervisory board approved the 2025 semi-annual report, confirming that the report accurately reflects the company's actual situation without any false records or misleading statements [1][2] - The supervisory board also approved the special report on the use of raised funds, agreeing with the board's assessment and committing to ensure compliance in the management of these funds [2] Group 2 - The meeting was conducted in accordance with the Company Law and the company's articles of association, ensuring proper governance [1] - The supervisory board will actively supervise the board and management to ensure effective measures are taken for the proper use of raised funds, protecting the interests of the company and all shareholders [2] - Relevant documents, including the semi-annual report and the special report on the use of raised funds, were disclosed on designated information platforms [1][2]

Group 1 - The company held its 10th meeting of the second Supervisory Board, which was conducted via communication, with all 5 supervisors present, ensuring compliance with relevant laws and regulations [1] - The Supervisory Board approved the 2025 semi-annual report and its summary, confirming that the report accurately reflects the company's actual situation and complies with legal requirements [1][2] - The board also approved the special report on the storage and actual use of raised funds for the first half of 2025, confirming compliance with regulations and no misuse of funds [2] Group 2 - The board agreed to cancel the Supervisory Board and transfer its powers to the Audit Committee of the Board, while also approving a capital increase of 4.90 shares for every 10 shares held, totaling 115,743,812 shares [2][3] - The proposal to change the registered capital and amend the company's articles of association will be submitted to the shareholders' meeting for approval [3]

Meeting Overview - The fourth meeting of the Supervisory Board of Suzhou Minxin Microelectronics Technology Co., Ltd. was held on August 28, 2025, in accordance with legal and regulatory requirements [1]. Financial Report Approval - The Supervisory Board approved the 2025 semi-annual report, confirming that its preparation and review complied with relevant laws and regulations, and accurately reflected the company's financial status and operational results for the first half of 2025 [2][3]. Fund Management - The management and actual use of raised funds for the first half of 2025 were found to be in compliance with regulatory guidelines, ensuring that funds were stored in dedicated accounts and used for specified purposes without any violations [2][3]. Auditor Appointment - The Supervisory Board agreed to appoint Zhihong Accounting Firm as the financial and internal control auditor for the year 2025, with the decision pending approval at the upcoming shareholders' meeting [3]. Asset Impairment Provision - The decision to recognize asset impairment provisions for the first half of 2025 was deemed appropriate and compliant with accounting standards, ensuring accurate financial reporting without harming the interests of shareholders [4].

Group 1 - The board of directors of Wuhan San Zhen Industrial Holdings Co., Ltd. held its 43rd meeting on August 28, 2025, with all 11 directors present, complying with the Company Law and the company's articles of association [1][2] - The meeting approved the 2025 semi-annual report and summary, which had been reviewed by the audit committee [1] - The company established a "Market Value Management Measures" in accordance with various regulatory guidelines to enhance market value management [2] - The company revised its "Fundraising Management Measures" to improve the efficiency of fundraising usage, aligning with new legal regulations effective from July 1, 2024, and March 28, 2025 [2]

Meeting Overview - The 21st meeting of the 4th Supervisory Board of Suzhou Ruikeda Connection System Co., Ltd. was held on August 28, 2025, with all three supervisors present [1][2]. Financial Report Approval - The Supervisory Board approved the 2025 semi-annual report, confirming that the report's preparation and review procedures comply with legal regulations and internal management systems, accurately reflecting the company's financial status and operational results [2][3]. Fund Management Report Approval - The Supervisory Board approved the special report on the management and actual use of raised funds for the first half of 2025, stating that the management of these funds complies with relevant regulations and that the disclosed information is accurate and complete [2][3]. Idle Fund Management Approval - The Supervisory Board approved the use of up to RMB 200 million of idle self-owned funds for cash management in safe and liquid investment products, ensuring that this will not affect the company's normal operations or the interests of shareholders, particularly minority shareholders [3].

Summary of Key Points Core Viewpoint - Beijing Shoulv Hotel Group Co., Ltd. has reported on the management and usage of raised funds for the first half of 2025, highlighting compliance with regulatory requirements and detailing the allocation of funds for hotel expansion and upgrades. Fundraising Overview - The company was approved to issue 134,348,410 shares at a price of RMB 22.33 per share, raising a total of RMB 2,994,275,995.30, with net proceeds of RMB 2,990,790,514.72 after deducting issuance costs [1][2] - As of June 30, 2025, the company has utilized RMB 1,619,257,322.74 for hotel expansion and upgrades, and RMB 900,000,000.00 for repaying bank loans, totaling RMB 2,519,257,322.74 in usage, leaving a balance of RMB 471,533,191.98 [1][2] Fund Management - The company has established a dedicated fund management system, ensuring that raised funds are stored and managed in specialized accounts [1][2] - As of June 30, 2025, the balance in the fundraising special account was RMB 44,641,805.17, including interest income [1][2] Investment Projects - The company has approved the use of RMB 153,479,401.99 to replace self-raised funds previously invested in hotel expansion and upgrades [2][3] - There were no instances of using idle funds to temporarily supplement working capital as of June 30, 2025 [2][3] Cash Management - The company has utilized idle funds for cash management, investing a total of RMB 8,550,000,000.00 in financial products, with RMB 8,000,000,000.00 redeemed upon maturity [3][6] - As of June 30, 2025, the company has not recovered the principal of RMB 55,000,000.00 from the financial products purchased with idle funds [3][6] Compliance and Reporting - The company has adhered to regulatory requirements and internal management protocols, ensuring accurate and timely disclosure of fundraising usage and management [2][3][6] - There have been no violations in the management and usage of raised funds as of June 30, 2025 [2][3][6]